Enanta Highlights RSV Polymerase Inhibitor Data At ESCMID 2025 In Vienna
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Top Premarket Gainers
Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Enanta Pharmaceuticals to Present Data for Its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
There's No Escaping Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Muted Revenues Despite A 38% Share Price Rise
Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
Strong Week for Enanta Pharmaceuticals (NASDAQ:ENTA) Shareholders Doesn't Alleviate Pain of Three-year Loss
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20
Enanta Pharmaceuticals (ENTA) Receives a Buy From Evercore ISI
Enanta Pharmaceuticals Advances in Virology and Immunology
Enanta Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Enanta Pharmaceuticals Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS Estimate.
The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts